Product image of Omnipaque 350mg/50ml (Iohexol USP) 350mg/ml x 50ml Vials supplied by GNH India

Omnipaque 350mg/50ml

Active Ingredient:
Iohexol USP
Form:
Vials
Brand:
Omnipaque 350mg/50ml
Origin:
China

Omnipaque 350mg/50ml (Iohexol USP Vials) 350mg/ml x 50ml

Iohexol, the active ingredient in Omnipaque 350mg/50ml, is a nonionic iodinated contrast media presented as a 350mg/ml injection solution in a 50ml vial for intravenous use. It is used to enhance contrast in various imaging studies, including computed tomography (CT), angiography, urography, and myelography.

GNH India supplies Omnipaque 350mg/50ml as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide.

Strength

350mg/ml x 50ml

Pack Size

1s

Storage

Ambient

Manufacturer / TM Owner

GE Healthcare Shanghai Co Ltd

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

Omnipaque 350mg/50ml is a radiographic contrast agent used to enhance the visibility of internal structures in various imaging studies.

  • Computed Tomography (CT): Enhances contrast in CT scans for better visualization of internal structures.
  • Angiography: Improves the visibility of blood vessels during angiographic procedures.
  • Urography: Aids in the visualization of the urinary tract.
  • Myelography: Enhances the imaging of the spinal cord and spinal canal.

How It Works

  • Omnipaque 350mg/50ml works by providing X-ray attenuation through the delivery of iodine atoms. These iodine atoms absorb X-rays, enhancing the contrast in imaging studies, which allows for better visualization of internal structures. The nonionic nature of iohexol reduces the risk of adverse reactions compared to ionic contrast media.

Side Effects

Omnipaque 350mg/50ml may cause side effects, ranging from common to serious or rare.

Common Side Effects

  • Nausea: Feeling sick to the stomach.
  • Headache: Pain or discomfort in the head.
  • Dizziness: Feeling lightheaded or unsteady.
  • Flushing: A warm, reddened sensation in the skin.
  • Vomiting: Expelling stomach contents through the mouth.
  • Rash: Skin irritation or redness.

Serious or Rare Side Effects

  • Anaphylaxis: Severe allergic reaction requiring immediate medical attention.
  • Angioedema: Swelling of the face, lips, or throat.
  • Bronchospasm: Constriction of the airways.
  • Cardiac Arrest: Sudden stoppage of the heart.
  • Seizures: Uncontrolled electrical disturbances in the brain.

Precautions & Warnings

Omnipaque 350mg/50ml should be used with caution in certain situations to ensure patient safety.

  • Allergies: Inform your healthcare provider if you have any known allergies to iodinated contrast media.
  • Kidney Disease: Use with caution in patients with impaired kidney function.
  • Asthma: Patients with a history of asthma should be monitored closely.
  • Diabetes: Patients with diabetes should be monitored for potential kidney issues.
  • Pregnancy: The safety of Omnipaque 350mg/50ml during pregnancy has not been established.
  • Breastfeeding: The safety of Omnipaque 350mg/50ml during breastfeeding has not been established.
  • Store below 30°C: Keep in the original packaging to protect from light.

Avoid Interactions

Omnipaque 350mg/50ml may interact with other medications, requiring careful monitoring.

Major Interactions (Avoid)

  • Beta-Blockers: May increase the risk of severe allergic reactions.
  • Interleukin-2: May increase the risk of nephrotoxicity.
  • Metformin: May increase the risk of lactic acidosis in patients with kidney impairment.

Moderate Interactions (Monitor Closely)

  • Diuretics: May increase the risk of kidney damage.
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): May increase the risk of kidney damage.
  • Aminoglycosides: May increase the risk of kidney damage.

Frequently Asked Questions

Omnipaque 350mg/50ml is used as a radiographic contrast agent to enhance the visibility of internal structures in various imaging studies, including computed tomography (CT), angiography, urography, and myelography. It helps improve the clarity of images, making it easier for healthcare providers to diagnose and monitor medical conditions.

Iohexol, the active ingredient in Omnipaque 350mg/50ml, works by providing X-ray attenuation. The iodine atoms in iohexol absorb X-rays, enhancing the contrast in imaging studies. This allows for better visualization of internal structures, aiding in the diagnosis and monitoring of various medical conditions.

The dose of Omnipaque 350mg/50ml is determined by the healthcare provider based on the specific imaging procedure, the patient's age, weight, and overall health. It is important to follow the prescribed dosage and administration instructions provided by the healthcare provider.

The safety of Omnipaque 350mg/50ml during pregnancy has not been established. Pregnant women should consult their healthcare provider before using this medication to weigh the potential benefits against the risks.

To order Omnipaque 350mg/50ml from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. The team will ask you to confirm your trade or institutional credentials and will reply with pricing, availability, shipping, and the necessary import paperwork.

Omnipaque 350mg/50ml is a nonionic iodinated contrast media, which reduces the risk of adverse reactions compared to ionic contrast media. It is widely used for its effectiveness and safety profile in various imaging studies, including CT, angiography, urography, and myelography.

Omnipaque 350mg/50ml should be stored at a temperature below 30°C and kept in the original packaging to protect from light. It is important to follow the storage instructions provided to maintain the effectiveness and safety of the medication.

Omnipaque 350mg/50ml is administered intravenously by a healthcare professional. The administration method and dosage are determined by the specific imaging procedure and the patient's individual needs. It is important to follow the administration instructions provided by the healthcare provider.

The most serious risks associated with Omnipaque 350mg/50ml include anaphylaxis, angioedema, bronchospasm, cardiac arrest, and seizures. These reactions are rare but require immediate medical attention if they occur. Patients should be monitored closely during and after the administration of the medication.

Omnipaque 350mg/50ml should not be used by individuals with a known allergy to iodinated contrast media or those with severe kidney disease. Patients with a history of asthma or diabetes should be monitored closely. Pregnant and breastfeeding women should consult their healthcare provider before using this medication.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Iohexol USP

Omnipaque 300mg/50ml

Omnipaque 300mg/50ml

300mg/50ml Vials
Optiscan - 350

Optiscan - 350

350mg/100ml Vials
Omnipaque 300mg/100ml

Omnipaque 300mg/100ml

300mg/100ml Vials
Omnipaque 350mg/50ml

Omnipaque 350mg/50ml

350mg/50ml Vials

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT